Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Florida Pulmonary Group, PA

Neither a doctor nor a teaching hospital

Research payments

$195,113

68 payments

Through program year 2025, Central Florida Pulmonary Group, PA is reported as receiving $195,113 in research payments, across 68 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,600 2
2024 Research $28,073 6
2023 Research $33,636 11
2022 Research $44,849 8
2021 Research $35,520 35
2020 Research $23,814 4
2019 Research $25,621 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $65,179 13 payments
  2. AstraZeneca Pharmaceuticals LP $60,546 10 payments
  3. Genzyme Corporation $28,879 8 payments
  4. Insmed, Inc. $23,786 30 payments
  5. Respicardia, Inc. $16,100 6 payments
  6. CSL Behring $623 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $46,309 6 payments
  2. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $33,042 10 payments
  3. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $32,137 3 payments
  4. A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $28,879 8 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study $23,786 30 payments
  6. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $14,237 4 payments
  7. ZOLL Respicardia, Inc. Registry Study $7,000 1 payment
  8. ZOLL Respicardia, Inc. Registry Study $4,600 2 payments
  9. ZOLL Respicardia, Inc. Registry Study $4,500 3 payments
  10. A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis $623 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $16,100 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record